Home » Stocks » ZYME

Zymeworks Inc. (ZYME)

Stock Price: $35.44 USD -0.68 (-1.88%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 1.64B
Revenue (ttm) 31.33M
Net Income (ttm) -194.01M
Shares Out 46.17M
EPS (ttm) -3.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $35.44
Previous Close $36.12
Change ($) -0.68
Change (%) -1.88%
Day's Open 36.04
Day's Range 35.21 - 36.55
Day's Volume 214,832
52-Week Range 24.82 - 59.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These biotech stocks could have great long-term potential.

Other stocks mentioned: EDIT, IGMS, IONS, XNCR
3 days ago - The Motley Fool

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will pr...

2 weeks ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will pr...

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voti...

2 months ago - Business Wire

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 14.71% and -90.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the...

2 months ago - Business Wire

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Diana Hausman, M.D....

3 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will pre...

3 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

3 months ago - Business Wire

With the trading day about halfway over, the broad markets largely were pushing higher, except for the Dow Jones industrial average.

Other stocks mentioned: BB, LRCX, SHOP, ZM, BHP, DCPH, SQ
3 months ago - 24/7 Wall Street

The clinical-stage antibody treatment developer has a fair way to go before it gets a product to market -- but it's not going it alone.

4 months ago - The Motley Fool

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five a...

4 months ago - Business Wire

VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ende...

5 months ago - Business Wire

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will par...

5 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that James Priour, forme...

5 months ago - Business Wire

The company announced early data for an experimental cancer drug that disappointed investors.

5 months ago - The Motley Fool

Zymeworks said a third of patients responded to a high dose of its cancer treatment — and ZYME stock crashed to a four-month low Thursday. Shares hit their lowest point since September.

5 months ago - Investors Business Daily

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has beg...

5 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical...

6 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishment...

6 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will pre...

6 months ago - Business Wire

Investors need to pay close attention to Zymeworks (ZYME) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

ZYME has a set of 3 drug discovery/development platforms which have generated major deals from big pharma. Its self-owned asset ZW25 is inching closer towards registrational stage.

7 months ago - Seeking Alpha

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three a...

7 months ago - Business Wire

ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announ...

Other stocks mentioned: EXEL
7 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene...

7 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and D...

7 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commiss...

8 months ago - Business Wire

VANCOUVER, British Columbia & BURLINGAME, Calif.--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Ho...

8 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will part...

8 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the...

8 months ago - Business Wire

The opportunity is vast for Ontrak, Nano-X Imaging, and Zymeworks.

Other stocks mentioned: NNOX, OTRK
10 months ago - The Motley Fool

VICTORIA, BC, Sept. 17, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD.

10 months ago - PRNewsWire

Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 26.74% and 44.72%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the...

11 months ago - Business Wire

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference ca...

1 year ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime par...

1 year ago - Business Wire

Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Zymeworks Inc. (ZYME) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

Other stocks mentioned: AUPH, KOD
1 year ago - The Motley Fool

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

Other stocks mentioned: AUPH, XENE
1 year ago - The Motley Fool

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019.

1 year ago - Zacks Investment Research

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HE... [Read more...]

Industry
Biotechnology
IPO Date
Apr 28, 2017
Stock Exchange
NYSE
Ticker Symbol
ZYME
Full Company Profile

Financial Performance

In 2020, Zymeworks's revenue was $38.95 million, an increase of 31.84% compared to the previous year's $29.54 million. Losses were -$180.55 million, 24.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Zymeworks stock is "Strong Buy." The 12-month stock price forecast is 55.46, which is an increase of 56.49% from the latest price.

Price Target
$55.46
(56.49% upside)
Analyst Consensus: Strong Buy